Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Expects FDA Advisory Committee Review Of Muraglitazar

This article was originally published in The Pink Sheet Daily

Executive Summary

Bristol-Myers Squibb expects FDA will hold an advisory committee meeting to discuss the application for its dual PPAR agonist muraglitazar
Advertisement

Related Content

Bristol's Abatacept Launch Supply Limited Until FDA Clears Contract Facility
Bristol's Abatacept Launch Supply Limited Until FDA Clears Contract Facility
Drug Safety Issues Will Raise Regulatory Expectations, Bristol Says
Drug Safety Issues Will Raise Regulatory Expectations, Bristol Says
Abatacept Launch Will Be Bolstered By Unmet Need In RA Market – Bristol
Abatacept Launch Will Be Bolstered By Unmet Need In RA Market – Bristol
FDA Delays PPAR Development Pending Carcinogenicity Tests, Ligand Says
Merck Gets Second Chance On Dual PPAR: Will Co-Develop Bristol's Muraglitazar
Merck Gets Second Chance On Dual PPAR: Will Co-Develop Bristol's Muraglitazar

Topics

Advertisement
UsernamePublicRestriction

Register

PS058149

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel